Tilray Brands and MedMenIrwin Simon CEO Tilray Jan 10, 2021
This is a clear refraction of the fact that even now, before federal legalization, we’re building out our US infrastructure through cannabis adjacent products, putting the pieces in place to drive revenue growth today, and to allow us to hit the ground running, once legalization occurs and these assets can be more fully leveraged.
That being said, we view our ability to go on day one. As important in that process, which is why we invested in convertible notes of MedMen. We have multiple benefit options regarding MedMen. More broadly, we continue to build our strategic position through multiple turnovers, so that can we fully benefit from legalization when the time comes.
Cheers,
V